Oren Gilad Biography and Net Worth

CEO of Aprea Therapeutics

Oren Gilad, Ph.D., has served as Chief Executive Officer of Aprea Therapeutics since July 2022 and as President and a member of its Board of Directors since May 2022. He previously served as President and CEO of Atrin Pharmaceuticals, Inc., leading its transaction with Aprea Therapeutics. Dr. Gilad brings extensive experience across multiple phases of drug development. During his time at Atrin, he led development from idea through early stage into the clinical stage while securing financing to support pre-clinical and clinical development, regulatory, and intellectual property activities. Before founding Atrin in 2011, Dr. Gilad authored several high-impact scientific publications over a 13-year academic career, including one demonstrating the importance of the ATR pathway in cancer development and treatment. Dr. Gilad earned his doctorate from the University of California at Davis and his B.S. from the Hebrew University, Jerusalem, Israel.

What is Oren Gilad's net worth?: The estimated net worth of Oren Gilad is at least $209.45 thousand as of April 3rd, 2025. Gilad owns 345,620 shares of Aprea Therapeutics stock worth more than $209,446 as of October 7th. This net worth evaluation does not reflect any other investments that Gilad may own. Learn More about Oren Gilad's net worth.
How do I contact Oren Gilad?: The corporate mailing address for Gilad and other Aprea Therapeutics executives is 3805 Old Easton Road, Doylestown, PA, 18902. Aprea Therapeutics can also be reached via phone at (215) 948-4119 and via email at [email protected]. Learn More on Oren Gilad's contact information.
Has Oren Gilad been buying or selling shares of Aprea Therapeutics?: Oren Gilad has not been actively trading shares of Aprea Therapeutics in the last ninety days. Most recently, on Thursday, April 3rd, Oren Gilad bought 5,500 shares of Aprea Therapeutics stock. The stock was acquired at an average cost of $1.84 per share, with a total value of $10,120.00. Following the completion of the transaction, the chief executive officer now directly owns 345,620 shares of the company's stock, valued at $635,940.80. Learn More on Oren Gilad's trading history.
Who are Aprea Therapeutics' active insiders?: Aprea Therapeutics' insider roster includes Lars Abrahmsen (SVP), Eyal Attar (SVP), Marc Duey (Director), Oren Gilad (CEO), John Hamill (CFO), and Gregory Korbel (SVP). Learn More on Aprea Therapeutics' active insiders.
Are insiders buying or selling shares of Aprea Therapeutics?: In the last year, Aprea Therapeutics insiders bought shares 2 times. They purchased a total of 26,459 shares worth more than $30,957.03. The most recent insider tranaction occured on December, 10th when Director Marc Duey bought 21,459 shares worth more than $25,107.03. Insiders at Aprea Therapeutics own 10.5% of the company. Learn More about insider trades at Aprea Therapeutics.
Information on this page was last updated on 12/10/2025.

Oren Gilad Insider Trading History at Aprea Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/3/2025	Buy	5,500	$1.84	$10,120.00	345,620
10/23/2024	Buy	500	$3.92	$1,960.00	333,395
10/14/2024	Buy	1,000	$2.59	$2,590.00	332,645
10/10/2024	Buy	150	$2.54	$381.00	331,645
3/13/2024	Buy	2,000	$7.29	$14,580.00	324,770

Oren Gilad Buying and Selling Activity at Aprea Therapeutics

Aprea Therapeutics Company Overview

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Today's Range

Now: $0.61

$0.58

$0.64

50 Day Range

MA: $0.73

$0.60

$0.98

2 Week Range

Now: $0.61

$0.55

$1.69

Volume

248,511 shs

Average Volume

898,562 shs

Market Capitalization

$7.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66